MGL Inhibitor Compounds Elevate 2-AG for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic cannabinoid agonists provide analgesic and anti-inflammatory effects but are difficult to separate from unwanted side effects, necessitating an alternative approach to enhance endocannabinoid signaling by elevating 2-AG levels, which can be achieved through the inhibition of monoacylglycerol lipase (MGL).
Innovation Solution
Development of specific MGL inhibitors, such as compounds of formula (I), which are designed to inhibit MGL activity, thereby increasing the levels of 2-AG, an endocannabinoid of high abundance in the CNS and gastrointestinal tract, to treat pain, inflammation, and CNS disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic cannabinoid agonists are used to treat pain and inflammation, then analgesic and anti-inflammatory effects are achieved, but unwanted side effects occur that are difficult to separate from the therapeutic effects
Solution Approach 1:
The patent extracts and targets the specific enzyme MGL responsible for degrading 2-AG, rather than directly activating cannabinoid receptors with synthetic agonists. By inhibiting MGL, the body's natural 2-AG levels are elevated, producing therapeutic effects through the endocannabinoid system without the side effects associated with synthetic cannabinoid agonists.
Solution Approach 2:
The patent uses MGL inhibition as an intermediary mechanism to indirectly elevate 2-AG levels and activate cannabinoid receptors. Instead of directly administering synthetic cannabinoid agonists that bind to CB1 and CB2 receptors, the compound of formula (I) inhibits MGL, allowing the body's own 2-AG to act as the mediator that naturally activates these receptors with fewer side effects.
2Object-affected harmful factors
If MGL inhibition is used to elevate 2-AG levels, then analgesic and anti-inflammatory effects are achieved with minimized side effects, but specific and potent MGL inhibitors with appropriate pharmacokinetic properties must be developed
Solution Approach 1:
The patent systematically varies structural parameters of the compound of formula (I), including substitutions at positions R1-R6, to optimize MGL inhibition potency and selectivity. By modifying parameters such as aromatic ring substitutions, heteroatom types, and side chain lengths, the compound achieves enhanced MGL inhibitory activity with improved pharmacokinetic properties while maintaining minimized side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MGL inhibitors effectively elevate 2-AG levels, providing analgesic and anti-inflammatory effects while minimizing side effects, making them potentially useful for treating pain, inflammation, and CNS disorders without the drawbacks of synthetic cannabinoid agonists.
Implementation Method 1
2-AG is hydrolyzed by monoacylglycerol lipase (MGL)
Data Source
AI summary
Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I), wherein Y, r, R2 and Z are defined herein.